Lattice Biologics Ltd. (LBLTF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | 536.15 Thousand | 161.62 Thousand | 264.09 Thousand |
| Net Income | - | - | - | -1.48 Million | -1.01 Million | -1.23 Million |
| Depreciation & Amortization | - | - | - | 380.9 Thousand | 204.09 Thousand | 201.18 Thousand |
| Deferred income taxes | - | - | - | - | 38.91 Thousand | -675.32 Thousand |
| Stock-based compensation | - | - | - | - | 21 Thousand | 154.85 Thousand |
| Change in working capital | - | - | - | 1.67 Million | 667.11 Thousand | 1.5 Million |
| Other non-cash items | - | - | - | -35.23 Thousand | 242.41 Thousand | 307.65 Thousand |
| Investing Cash Flow | - | - | - | -592.07 Thousand | -51.96 Thousand | -230.78 Thousand |
| Investments in PPE | - | - | - | -592.07 Thousand | -51.96 Thousand | -230.78 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | 97.47 Thousand | -100.44 Thousand | -45.67 Thousand |
| Debt repayment | - | - | - | -224.02 Thousand | -100.44 Thousand | -45.67 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | 321.5 Thousand | - | - |
| Accounts receivables | - | - | - | -25.83 Thousand | -108.17 Thousand | 45.36 Thousand |
| Accounts payables | - | - | - | 1.5 Million | 42.26 Thousand | 1.19 Million |
| Inventory | - | - | - | 184.64 Thousand | 780.5 Thousand | 363.92 Thousand |
| Other working capital | - | - | - | 8269.00 | -47.48 Thousand | -99.88 Thousand |
| Cash at beginning of period | - | - | 57.21 Thousand | 15.66 Thousand | 6448.00 | 18.82 Thousand |
| Cash at end of period | - | - | 57.21 Thousand | 57.22 Thousand | 15.66 Thousand | 6448.00 |
| Capital Expenditure | - | - | - | -592.07 Thousand | -51.96 Thousand | -230.78 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | - | - | 41.55 Thousand | 9221.00 | -12.37 Thousand |
| Free Cash Flow | - | - | - | -55.92 Thousand | 109.66 Thousand | 33.3 Thousand |
| Breakdown | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | - | - | - | - |
| Other non-cash items | - | - | - | - | - | - |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | - | - | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | - | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | - | - | - | - | - | - |
| Cash at end of period | - | - | - | - | - | - |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
PTG-R
4264
SAH
6925
BTSDF
SEV